Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

First-in-human (FIH) Phase I Trial of BS-006 in Cervical Cancer (CC-OV01)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05393440
Recruitment Status : Not yet recruiting
First Posted : May 26, 2022
Last Update Posted : June 7, 2022
Sponsor:
Collaborator:
Wuhan Binhui Biotechnology Co., Ltd.
Information provided by (Responsible Party):
Hui Qiu, Wuhan University

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This is a two-stage phase I clinical trial with oncolytic viruses BS-006 in recurrent or metastasis cervical cancer patients who failed in second line treatment.

Condition or disease Intervention/treatment Phase
Uterine Cervical Neoplasms Biological: BS-006 Phase 1

Detailed Description:
This trial includes accelerated dose-escalation stage and dose-expansion stage. An engineered modification oncolytic viruses, BS-006, derived from type II herpes simplex virus strain are planed to be injected into the tumor every two weeks until disease progression or unacceptable toxicity or withdrawn of consent or no lesion suitable for injection or death. In dose-escalation stage, there are three dose levels (1 million, 10 millions, 100 millions 50 % cell culture infectious dose (CCID50)/ml) . Treatment dose will escalate to next higher level if no dose limiting toxicity happens for one time of injection in 3 subjects. Maximal tolerable dose is defined as the highest dose with no more than one dose limiting toxicity and is recommended for dose expansion stage. In dose-expansion stage, 15 subjects will be enrolled. BS-006 viruses will be injected into proper tumor lesions every 2 weeks until disease progression or unacceptable toxicity or withdrawn of consent or no lesion suitable for injection or death. Radiology assessment will repeat every 6 weeks. Dose interruption, not reduction, is permitted in this stage.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 18 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A First-in-human Phase I Two-stage Clinical Trial for Intratumoral Injection of Recombinant Oncolytic Type II Herpes Simplex Virus (BS-006) in Patients With Recurrent Cervical Cancer
Estimated Study Start Date : July 1, 2022
Estimated Primary Completion Date : July 1, 2023
Estimated Study Completion Date : July 1, 2024

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Dose-escalation cohort
Three subjects will be enrolled in this cohort. First subject will receive first injection in dose level of 1 million CCID50/mL. If tolerated, second injection for this subject will be accelerated to 10 millions CCID50/mL. If tolerated, the third injection will be further accelerated to 100 million CCID50/mL. The maximum volume for per injection time point is 8 mL. Injection will repeat every two weeks until disease progression or unacceptable toxicity or withdrawn of consent or no lesion suitable for injection or death. If dose limiting toxicity (DLT) happens in any dose level, the injection dose will be decrease to the last tolerable level.
 Biological: BS-006
BS-006 is an engineered recombinant type II herpes simplex virus (HSV2) designed and produced by Wuhan Binhui Biopharmaceutical Co., Ltd. It was derived from HSV2 strain HG52. ICP34.5 and ICP47 genes were deleted to ensure abortive infection and immune destruction in normal cells. Bispecific T cell engager of anti-CD3 antibody and anti-PD-L1 antibody were constructed and inserted into HG52 strain genome.
Other Name: Recombinant oncolytic type II herpes simplex virus
Experimental: Dose-expansion cohort
Fifteen subjects will be enrolled in this cohort. The maximal tolerable dose (MTD) confirmed in the first stage will be utilized in 15 patients. This stage should not be initiated before the completion of dose escalation of all three subjects in the first stage. Treatment will be repeated every two weeks until disease progression or unacceptable toxicity or withdrawn of consent or no lesion suitable for injection or death. Dose interruption, not reduction, is permitted. Treatment will be terminated if toxicity-related treatment interrupt is longer than 28 days. Radiology assessment will be conducted every six weeks.
 Biological: BS-006
BS-006 is an engineered recombinant type II herpes simplex virus (HSV2) designed and produced by Wuhan Binhui Biopharmaceutical Co., Ltd. It was derived from HSV2 strain HG52. ICP34.5 and ICP47 genes were deleted to ensure abortive infection and immune destruction in normal cells. Bispecific T cell engager of anti-CD3 antibody and anti-PD-L1 antibody were constructed and inserted into HG52 strain genome.
Other Name: Recombinant oncolytic type II herpes simplex virus


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Maximal tolerable dose [ Time Frame: 2 months after initiation of enrollment ]
    The dose level at which there is no more than one DLT happens in dose-escalation stage

  2. Rate and grade of adverse events [ Time Frame: From enrollment to 90 days after last treatment of all subjects ]
    The incidence of adverse events and severity graded according to CTCAE 5.0

  3. Cope numbers of BS-006 [ Time Frame: 1 hours predose and 0.5 hours post-dose for first three doses and 1 hours predose ever after ]
    Detection of BS-006 virus copy numbers in urine, stool, saliva, blood and wiper of injection point and perineum


Secondary Outcome Measures :
  1. Tumor response rate [ Time Frame: Up to 2 years ]
    Tumor change assessed by investigator according to RECIST 1.1

  2. Abscopal effect rate [ Time Frame: Up to 2 years ]
    Rate of subjects who showed tumor shrinkage for any untreated lesion

  3. Progression free survival rate [ Time Frame: Up to 2 years ]
    Proportion of participants without tumor recurrence or death

  4. Overall survival rate [ Time Frame: Up to 2 years ]
    Proportion of survival participants


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Older than 18 years old and younger than 75 years old;
  2. Zubrod-ECOG-WHO performance status is 0-1;
  3. Life expectancy is longer than 3 months;
  4. Pathologically proven malignant tumor originating from cervix uterine. All pathological types are acceptable except for sarcoma of any subtypes;
  5. Radiological confirmed progression after at least 2 lines prior treatment or intolerable toxicity events occur during the second or later line treatment: 1) Neoadjuvant or adjuvant chemotherapy for no less than 2 cycles should be regarded as a separate treatment line if disease progress within 6 months after treatment finish;2) Regional treatment such as brachytherapy, radiofrequency ablation and artery embolization therapy should not be considered as a treatment line; 3) Treatment shift due to toxicity without radiological progression should not be counted as a separate line;
  6. At least one measurement lesion according to RECIST 1.1;
  7. At least one lesion with maximum diameter is larger than 1cm and surgically accessibility;
  8. Patients must have recovered from prior treatment related toxicity to CTCAE grade 1 or 0;
  9. Time interval to last systematic treatment or radiation affecting more than 20% bone marrow must be more than 4 weeks;
  10. Time interval to last major surgery must be more than 4 weeks;
  11. Abundant organ function: 1) Absolute neutrophil count is more than 1500/mm3 without granulocyte colony stimulating factor in the prior 7 days or long-acting granulocyte colony stimulating factor in the prior 20 days; platelets count is more than 100,000/mm3 without thrombopoietic drugs in the prior 7 days or platelet transfusion in the prior 10 days; hemoglobin is more than 9.0g/dL without red blood cell transfusion in the prior 20 days; 2) Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) are lower than 2.5-fold upper limit of normal (ULN); serum bilirubin is lower than 1.5-fold ULN; serum albumin is more than 3g/dL; 3) Serum creatinine is lower than 1.5-fold ULN; 4) Prothrombin time and activated partial thromboplastin time is lower than 1.3-fold ULN;
  12. Patients must have fully recovered from suspected or diagnosed genital herpes beyond 3 months;
  13. Patients or their legally authorized representative must be willing and able to sign the informed consent form (ICF) and to adhere to the protocol requirement;
  14. Women of childbearing potential must agree to use highly effective contraceptive methods in while on study drug and for at least 3 months after the last injection of BS-006. The pregnancy test within 7 days prior to the first injection must be negative.

Exclusion Criteria:

  1. Cervical sarcoma of any subtype or prior history of other malignancy within 5 years;
  2. Central nerve system metastasis;
  3. Lesions met the requirement outlined in the inclusion criteria are unsafe for injection evaluated by investigators;
  4. Severe comorbidities of any organs, including but not limit to myocardial infarction within 6 months, unstable angina pectoris, congestive heart failure, grade 3 or higher hypertension per CTCAE, cardiac arrhythmias, uncontrolled diabetes, fever of unknown reason, active digest ulcer and chronic obstructive pulmonary disease;
  5. History of central nervous system infectious or demyelinating disease;
  6. Severe infectious disease requiring constant antibiotic treatment;
  7. Systematic glucocorticoids use within 2 weeks or glucocorticoids need for a long term;
  8. Active infection of hepatitis B or C, HIV, cytomegalovirus, syphilis or other virus requiring treatment;
  9. Immune disorder disease;
  10. Antiviral treatment of any kinds;
  11. Prior participant in experimental viral therapy;
  12. Allergy to herpes simplex virus vaccine;
  13. Participation in another research study within 4 weeks;
  14. Poor compliance or incapacitated patients due to mental illness or other reasons;
  15. Pregnancy or lactation.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05393440


Contacts
Layout table for location contacts
Contact: Shaoxing Sun, M. D. +08613871286154 sunshaoxing@whu.edu.cn

Locations
Layout table for location information
China, Hubei
Zhongnan Hospital of Wuhan University
Wuhan, Hubei, China, 430071
Sponsors and Collaborators
Zhongnan Hospital
Wuhan Binhui Biotechnology Co., Ltd.
Investigators
Layout table for investigator information
Principal Investigator: Hui Qiu, Ph. D. Wuhan University
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Publications:

Layout table for additonal information
Responsible Party: Hui Qiu, Chief Physician and Director of Department of Radiation and Clinical Oncology (Gynaecological Oncology, Wuhan University
ClinicalTrials.gov Identifier: NCT05393440    
Other Study ID Numbers: CC-OV01
First Posted: May 26, 2022    Key Record Dates
Last Update Posted: June 7, 2022
Last Verified: June 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Hui Qiu, Wuhan University:
Uterine Cervical Neoplasms
Oncolytic viruses
BS-006
Phase I clinical trial
Investigator initiated trial
Additional relevant MeSH terms:
Layout table for MeSH terms
Uterine Cervical Neoplasms
Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
 Urogenital Neoplasms
Neoplasms by Site
Uterine Cervical Diseases
Uterine Diseases